Solid phase extraction of novel synthetic 2-benzyl benzimidazole opioid compounds 'nitazenes'

In this application note, UCT, Inc. introduces a method to tackle the emerging threat of 2-benzyl benzimidazole opioids or 'nitazenes'. Originally developed as potential analgesics in the 1950s but never approved for medical use, these highly potent synthetic opioids are now resurfacing, posing a significant risk in the ongoing opioid epidemic. The note outlines a targeted extraction method for the analysis of nine nitazene compounds from urine and blood, utilizing UCT’s Clean Screen^® DAU column and new SelectraCore^® C18 core-shell column.